Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027508 · ClinicalTrials.gov registry record · Phase 2
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
A Phase 2 study, sponsored by PharmaMar.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00027508 is a Phase 2 study that was terminated before completion, run by PharmaMar.
The verdict
NCT00027508, a Phase 2 study, was terminated before completion, sponsored by PharmaMar.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.
Interventions
- DRUG trabectedin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027508
The ClinicalTrials.gov registry entry for NCT00027508 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which trabectedin is the first listed.
NCT00027508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027508 about?
NCT00027508 is a clinical study titled "Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.
What is the current status of trial NCT00027508?
This trial is currently terminated. It is a Phase 2 study. The study started on 2001-07. Estimated completion is 2002-02.
What interventions are being tested in trial NCT00027508?
The interventions under investigation include: trabectedin (DRUG).
Who is sponsoring clinical trial NCT00027508?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.